Author/Authors :
Velija-Asimi, Zelija Clinical Centre University of Sarajevo - Clinic of Endocrinology, Diabetes and Metabolism diseases, Bosnia and Herzegovina , Izetbegovic, Sebija General hospital “Prim. Dr Abdulah Nakaš”, Bosnia and Herzegovina , Karamehic, Jasenko Clinical Centre University of Sarajevo - Department of Clinical Immunology, Bosnia and Herzegovina , Coric, Jozo Clinical Centre University of Sarajevo - Clinic for Clinical Biochemistry, Bosnia and Herzegovina , Panjeta, Mirsad Clinical Centre University of Sarajevo - Clinic for Clinical Biochemistry, Bosnia and Herzegovina , Macic-Dzankovic, Amra General hospital “Prim. Dr Abdulah Nakaš”, Bosnia and Herzegovina , Djelilovic-Vranic, Jasminka Clinical Centre University of Sarajevo - Clinic of Neurology, Bosnia and Herzegovina , Dizdarevic-Bostandzic, Amela Clinical Centre University of Sarajevo - Clinic of Endocrinology, Diabetes and Metabolism diseases, Bosnia and Herzegovina
Abstract :
Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of antihyperglycemic drugs that block degradation of incretin hormones. Goal: To assess the effects of treatment with DPP-4 inhibitors on glucoregulation and body weight in obese patients with type 2 diabetes mellitus. Patients and methods: The study included 9 females and 9 males with type 2 diabetes (n=18), BMI=31.24±2,26 kg/m2, mean age 58 ±6,8 years. The patients have been thoroughly evaluated before treatment, and 6 months after treatment with DPP-4 inhibitor (sitagliptin) in combination with metformin. Results: After 6 months of treatment with DPP-4 inhibitors in combination with metformin HbAlc (-1,49%)., FBG (-3.75 mmol/L) and PBG (-5.79 mmol/L) significantly reduced (p=0.000). Mean body weight also significantly reduced (-12.5%; p=0.000).Reduction of mean fasting insulin was 5.46 mIU/L or 27% (p=0.000). Mean HOMA-IR change was −1.64 (p=0.000). Also there was significant decreasing of systolic blood pressure (p=0.001), cholesterol (p=0.004), triglycerides (p=0.001), LDL (p=0.002) and increasing of HDL (p=0.002).Hypoglycaemia was not registered in any of the patients. Conclusion: These results show that in obese patients with type 2 diabetes, DPP-4 inhibitors treatment in combination with metformin was associated with improvements in glycaemic control, and a reduction in body weight.
Keywords :
Dipeptidyl peptidase , 4 inhibitors , metformin , type 2 diabetes , obesity
